Sami Labs Limited

Sami-sabinsa Group Limited

Other

Sabinsa Corporation

Semi Labs Limited

Ramanujam, Rajendran

Mundkur, Lakshmi

Beede, Kirankumar

Majeed, Shaheen

Arumugam, Sivakumar

Ali, Furqan

Thomas, Samuel Manoharan

Majeed, Anju

Nagabhushanam, Kalyanam

Prakash, Subbalakshmi

Kalyanam Nagabhushanam

Muhammed Majeed

Sivakumar Arumugam

Furqan Ali

Lakshmi Mundkur

Anjali Pandey

Shaheen Majeed

Sarang Bani

Rajendran Ramanujam

Beena Bhat

Subbalakshmi Prakash

Samuel Manoharan Thomas

Anju Majeed

Kirankumar Beede

Priti Vaidyanathan

Renukeshwar H Chandramouli

Natarajan Sankaran

Keshava Rapole

Savita Ganjihal

Ravikrishna Chebolu

Douglas Kalman

Rattan Sood

Suresh Karri

Krishnamani Jayaraman

Anurag Pande

Geetha Kanhangad-Gangadharan

Susmitha Anand

Jeffrey Reinhardt

Muthuraman Gnanamani

Mitchell Chavez

Rajinder Kumar Bammi

Nagarajan Ananthanarayanan

Arvind Kumar

A Muhamad Ibrahim

Ugraiah Amilineni

Sivaprakash Kurumanghat Balakrishnan

Nagarajan Muthukaman

Pritee Paliwal

Kulithalai Viswanathan Krishnamurthy

Pentakota Paradesi Naidu

Sivaprskash Kurumanghat Balakrishnan

Mohammad Mansoor Ansari

Kiran Trineshwaraiah-Sirsalmath

Ambady Rajagopalan

Nooruddin Thajuddin

Krishnamurthy Kulithalai Viswanathan

Samuel Thomas Manoharan

John Adams Sebastian

Jamsheeda Moothedath

Prasad M Peethambaran

Mahadeva Nayak

Hosahalli Prabhakara Hemantha

Bani Sarang

Jefferey Reinhardt

Susmitha Anand Tathapudi

Susmitha Anand-Tathapudi

Sakthivel Palaniappan

Rajasekharan Parthasarathy

Majeed Muhammed

The present invention discloses a novel fructophilic lactic acid producing bacteriastrain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Fructophilic lactic acid producing bacteria

The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

Process for the synthesis of calebin-a and its intermediates

The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

Compositions for management of polycystic ovary syndrome

A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises aextract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.

Compositions for management of acute nephrotoxicity

The present invention discloses a method of isolating secondary metabolites, specifically arjunolic acid, from the calli and/or the suspension cultures derived from the pluripotent cambium tissue of. The invention also discloses a method of inducing callus, establishing and maintaining suspension cultures of callus derived from the cambium offor the isolation of secondary metabolites.

Method of isolating secondary metabolites from cambium derived callus cultures

The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises β-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

Compositions for targeting receptor for advanced glycation end-products (RAGE) in a chronic inflammatory condition

The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Compositions for managing chronic obstructive pulmonary disease

The invention discloses a composition comprisingextract andextract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

Process and compositions for enhancing energy expenditure

Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated fromMTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated fromMTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Skin care applications of extracellular metabolites from Bacillus coagulans

The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Therapeutic compositions and methods for pulmonary fibrosis

The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Curcuminoid composition for therapeutic management of metabolic syndrome

The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.

Curcuminoid composition and its therapeutic potential in managing lung fibrosis

Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of &#x3b2; secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of &#x3b2; secretase mediated disorders.

Compositions and methods for beta secretase inhibition

The present invention discloses the potential of probiotic bacteriaindividually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprisingand multi-enzyme complex in mammals.

Method and composition for therapeutic management of gluten intolerance

The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprisingMTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprisingMTCC 5856 individually or in combination with anthocyanins.

Compositions and methods for management of atrophic gastritis and colitis

Growing community of inventors

East Windsor, NJ, United States of America

Kalyanam Nagabhushanam